Home Shares 4 biotechs with major news coming this year

4 biotechs with major news coming this year

The fact of biotech investing is that the share prices are at the mercy of news flow from drug trial results, partnerships with bigger companies, regulatory interactions and a wide range of other events that can point to the increased – or decreased – likelihood of the drug, medical device or diagnostic test ever reaching the market.

This article is for Switzer Report subscribers

Already a subscriber? Log in to access this article.

The Switzer Report is our premium investment service, built to give serious investors clarity, confidence and practical direction. Join thousands of subscribers who already rely on our leading, independent Australian investment content.

As a subscriber, you'll receive:

Actionable investment ideas across Australian and global markets
Model portfolios to help guide asset allocation and stock selection
Weekly investment sessions with Peter Switzer, breaking down market moves and opportunities
Investor Q&A access, where your questions are answered by our experts
Timely insights to help you cut through the noise and focus on what matters

This isn't generic commentary — it's practical guidance designed to help you make smarter investment decisions.

Start Your 21-Day Free Trial

No commitment. Cancel anytime. Plans from $35/month.

“Switzer Report has been invaluable for my investment decisions. The expert analysis and stock picks have consistently helped me build wealth with confidence.”
★★★★★ — Michael J., subscriber since 2019
21-day free trial
Cancel anytime, no lock-in
Secure payment via Stripe

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.